Insider Buying: Enovis (NYSE:ENOV) Insider Buys 1,000 Shares of Stock

Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert bought 1,000 shares of the firm's stock in a transaction on Monday, June 1st. The shares were purchased at an average price of $22.22 per share, for a total transaction of $22,220.00. Following the completion of the transaction, the insider owned 49,640 shares of the company's stock, valued at $1,103,000.80. This represents a 2.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Oliver Engert also recently made the following trade(s):

• On Friday, March 13th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were purchased at an average price of $23.74 per share, for a total transaction of $23,740.00.
• On Monday, March 9th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were purchased at an average price of $23.39 per share, for a total transaction of $23,390.00.
• On Friday, March 6th, Oliver Engert bought 750 shares of Enovis stock. The shares were purchased at an average price of $24.41 per share, for a total transaction of $18,307.50.

Enovis Stock Down 1.9%

ENOV opened at $21.53 on Thursday. The business's fifty day moving average is $24.00 and its two-hundred day moving average is $24.85. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -1.08 and a beta of 1.38. Enovis Corporation has a one year low of $20.82 and a one year high of $36.82.

---

---

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts' consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of several recent research reports. William Blair initiated coverage on Enovis in a research report on Friday, April 17th. They issued an "outperform" rating on the stock. Wells Fargo & Company reduced their price objective on Enovis from $42.00 to $40.00 and set an "overweight" rating on the stock in a research report on Friday, May 8th. Wall Street Zen upgraded Enovis from a "hold" rating to a "buy" rating in a research report on Sunday, May 10th. Evercore restated an "outperform" rating and issued a $36.00 price objective on shares of Enovis in a research report on Friday, May 8th. Finally, Zacks Research downgraded Enovis from a "strong-buy" rating to a "hold" rating in a research report on Monday. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Enovis currently has an average rating of "Moderate Buy" and an average target price of $44.50.

Read Our Latest Report on ENOV

Institutional Trading of Enovis

Several institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System increased its stake in Enovis by 1.2% during the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company's stock worth $1,622,000 after acquiring an additional 621 shares during the last quarter. MGO One Seven LLC increased its stake in Enovis by 9.4% during the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company's stock worth $202,000 after acquiring an additional 650 shares during the last quarter. Rhumbline Advisers increased its stake in Enovis by 0.4% during the third quarter. Rhumbline Advisers now owns 173,023 shares of the company's stock worth $5,250,000 after acquiring an additional 682 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after acquiring an additional 707 shares during the last quarter. Finally, Empowered Funds LLC increased its stake in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock worth $249,000 after acquiring an additional 749 shares during the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Recommended Stories

• Five stocks we like better than Enovis
• Fifth Third’s Big Bet Is On
• Dell's AI Toll Bridge Is Paved with Record Margins
• As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingAI
• Coke's $10B India IPO Plan Pops the Top on Hidden Value

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].